References:

1. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909-3908.

2. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update [review]. Lancet Oncol. 2004;5(6):341-353.

3. O’Leary HM, Savage KJ. Novel therapies in peripheral T-cell lymphomas [review]. Curr Oncol Rep. 2008;134(5):202-207.

4. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15(10):1467-75.

5. Savage KJ. Peripheral T-cell Lymphomas. Blood Rev. 2007; 21:201-216.
 
ALLOS THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share information)
(unaudited)
 
  Three Months Ended   Year Ended
December 31, December 31,
2011   2010 2011   2010
Revenue:
Net product sales $ 15,435 $ 11,705 $ 50,486 $ 35,227
License and other revenue   1,476         30,583      
Total revenue 16,911 11,705 81,069 35,227
 
Operating costs and expenses:
Cost of sales, excluding amortization expense 1,293 1,317 4,510 3,647
Cost of license and other revenue 690 11,698
Research and development 4,622 8,303 22,189 31,359
Selling, general and administrative 11,419 21,631 67,817 78,782
Amortization of intangible asset   114     114     454     454  
Total operating costs and expenses   18,138     31,365     106,668     114,242  
Operating loss (1,227 ) (19,660 ) (25,599 ) (79,015 )
Interest and other income, net   11     1,518     85     1,520  
Loss before income taxes (1,216 ) (18,142 ) (25,514 ) (77,495 )
Income tax benefit           7     78  
Net loss   ($1,216 )   ($18,142 )   ($25,507 )   ($77,417 )
Net loss per share: basic and diluted   ($0.01 )   ($0.17 )   ($0.24 )   ($0.74 )
 

Weighted average shares: basic and diluted
  106,029,341     105,373,147     105,711,536     105,123,420  
 
 
ALLOS THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
 
  December 31,   December 31,
2011 2010
ASSETS
Cash, cash equivalents and investments $ 97,772 $ 98,565
Accounts receivable 15,259 12,076
Intangible asset, net 4,772 5,225
Other assets 2,798 2,645
Property and equipment, net   1,476   2,245
Total assets $ 122,077 $ 120,756
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities, excluding deferred revenue $ 17,443 $ 22,558
Deferred revenue 20,310
Stockholders’ equity   84,324   98,198
Total liabilities and stockholders’ equity $ 122,077 $ 120,756
 

If you liked this article you might like

Monday's Top 10 Articles, Videos on TheStreet

Spectrum Pharma: The Growth Party is Over

Allos Stock Gaps Down On Today's Open (ALTH)

Biotech Stock Mailbag: Amarin, Spectrum, Arena

Next Step for Amag's Board: Fire CEO, Sell the Company.

Next Step for Amag's Board: Fire CEO, Sell the Company.